Edgenation
8 years ago
NEWS!!! March 14, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd, will soon be entering the security inspection stage of its Health Canada Dealer’s License application to produce, gather or cultivate cannabis for scientific purposes.
Cannevert originally submitted its application on August 23, 2016 to Health Canada’s Office of Controlled Substances; this was processed as a continuation of our previous application by the group’s chemistry team. Cannevert currently holds a Health Canada scientific exemption which allows it to order a set total amount of cannabis using one Canadian licensed producer at a time. The new application will enable the team to produce "whole-plant" extracts, source from multiple licensed producers, and export cannabis materials for research purposes such as clinical trials being conducted overseas. Cannevert also indicated on its application that it would like to be on a public list of licensed laboratories able to conduct such activities with cannabis under the Narcotic Control Regulations; this list can be found at https://www.canada.ca/en/health-canada/services/list-licensed-dealers.html
This Dealer’s License will include analytical testing for persons who fall under the following Section 56 exemption, which is for registered persons and individuals responsible for them or authorized persons to provide, deliver, transport or send fresh and dried marijuana and cannabis oil to Licensed Dealers for analytical testing. Cannevert also indicated that it would like to perform analytical testing of cannabis samples received from holders of a valid license issued under the Industrial Hemp Regulations.
Cannevert has been notified that the company will be undergoing a security inspection soon. Veritas CEO, Lui Franciosi stated, “We are pleased with the status of Cannevert’s Dealer’s License Application. Reaching the security inspection stage means that the company is getting closer to being one of the few labs in Canada allowed to perform analytical testing and biological screening of cannabis and hemp for licensed producers. The License also complements Cannevert’s research, by removing existing barriers of supply, thereby enabling to progress in faster, more efficient and more comprehensive manner.
Acquisition of this Dealer’s License when combined with a commercial grower’s license will add significant value to Cannevert, Sechelt and Veritas.” (Sechelt Organic Marijuana Corp. was recently notified by Health Canada that it has successfully progressed into the Final Review stage of the ‘Access to Cannabis for Medical Purposes Regulations’ (ACMPR) application process).
About Sechelt Organic Medicine Inc.
Sechelt was formed to become a producer of medical marijuana under the ACMPR license. The products designed by Cannevert Therapeutics require the ability to grow specific strains of medical marijuana under ideal conditions. Sechelt provides Cannevert Therapeutics this ability. Veritas has entered into an acquisition agreement with the owners of Sechelt, subject to the issuance of ACMPR license.
artweed
8 years ago
Edgenation, I've read your posts on Veritas and thought I should chip in a post myself, since I have been researching and investing in Veritas for some time. I've scoured the company's website, read their investment presentation and market strategies, and compared them to the competition, and there's no doubt Veritas will emerge as a leading pharmaceutical research company and end up with many patents for its proprietary strains.
Among the key things that sold me on the company is their leadership team, which features blue-chip business executives and top-notch scientists and chemists. These guys know cannabis top to bottom and should be able to produce unique marketable products after successful clinical trials.
That said, everyone needs to bear in mind that Veritas, like many other small start-ups, is still a very early-stage cannabis company. They are still years away from earning significant profits because of the lengthy, intensive nature of human clinical trials. The good news is that this is one of the rare companies that I believe you can count on to actually achieve their long-term goals, and when that does happen the company will be worth hundreds of millions, not the US$10 million they're worth today.
Despite being early stage, there is still a lot of room for Veritas stock to go up in price in the near term. Veritas is rather overlooked and people will discover it as future news about milestones and getting government approvals is achieved. You and I are in on the ground floor, but there is still time for others to join us before the scope and credibility of the company is demonstrated.
Obviously, Marapharma is a company that recognized Veritas's stellar leadership when they made a major investment in the organization (which makes Marapharma a good investment as well).
Bottom line, unlike many small cannabis companies, Veritas will actually prove to be a huge winner in the coming years. I am willing to be patient and keep investing on the dips like we had today. It's good to see you are just as excited as I am, so keep the faith and keep posting those news updates!
Edgenation
8 years ago
NEWS!!!
Veritas Provides Update ACMPR and Cannabis Cultivation Facility and Production Methodology
March 5, 2017, Vancouver, B.C. Veritas Pharma Inc. "Veritas". (trading on: CSE: VRT - OTC: VRTHF - FSE: 2VP), pursuant to the news release dated February 20, 2017, was notified by Health Canada to be in the final review stage of its license application, announces additional details in regards to its marijuana growing strategy and facility.
The acquisition of Veritas' wholly owned subsidiary, Sechelt Organic Marijuana Corp. "Sechelt", is subject to certain terms and conditions, including obtaining a Health Canada ACMPR/MMPR license for the building of a cannabis growing facility. Since July 4th, 2014, Sechelt has had an application pending with Health Canada for said license. Sechelt leases with an option to purchase 0.73 acres of fenced, geo - tech industrial property in an approved jurisdiction to build a 2 story, 10,000 square foot MMPR facility in Sechelt, British Columbia, Canada. The plans for this facility include 6,800 sq. ft. of budding rooms, 3,000 sq. ft. of cloning rooms, as well as a small testing lab and secure storage room. The building and the security requirements have been designed and implemented in compliance with Canadian government requirements. Sechelt personnel include an experienced grow team, who meet all of the ACMPR licensing guidelines. Sechelt’s personnel utilize a unique “no till” technique, which results in the growth of consistent strains, which are both 100% organic and cost efficient. The proposed grow rooms are unique both in construction and design, with each unit meeting air flow management and electrical light requirements. Additionally, the growing method focuses on organic methods for soil management, and the complete exclusion of spraying any types of chemicals. Finally, the unique soil conditions and growing environment is designed to maximize both quality and quantity of marijuana produced.
Veritas CEO, Dr. Lui Franciosi, commented, “Our goal is to create shareholder value. To achieve this, we plan to create the most effective disease-resistant specific strains of marijuana, and to provide conclusive scientific evidence so doctors and patients alike can recommend and use our proprietary strains with confidence. A key portion of the strategy is to produce high quality, consistent marijuana plants. I am confident that with our strategy, which combines organic growing practices, industry leading testing standards, and scientific approaches to growing methods, we can produce the highest quality strains required for the branding of our proposed products. Good business allows for good revenue and good revenue allows for good profit and this too, is a goal for Veritas.”
Edgenation
8 years ago
NEWS!!! Veritas Pharms Receives Latest Research Report From Cannavert Therapeutics
February 24, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd, has been provided the Company with its latest research report outlining its progress with cannabis strains.
In Cannevert’s report, the strength and mix of research expertise and skillsets were highlighted along with the ‘lean and mean’ approach of being a discovery company. It also discussed the efficiency of identifying and quantifying all cannabinoids from various cannabis strains, the status of intellectual property protection of strains with therapeutic potential, and the plans for upcoming clinical trials in acute and chronic pain. There was also mention of some positive unexpected findings from animal studies, which will be further investigated and protected in due course. Pursuant to this study, initial meetings were made in the Netherlands with respect to the commencement of human trials.
Veritas CEO, Lui Franciosi stated, “We are pleased with the pace of Cannevert’s progress in identifying analgesic strains for clinical testing later this year. They have also made every effort to protect their findings with the help of Vancouver law firm, Oyen Wiggs Green & Mutala.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. Although Veritas has advanced $1,250,000 to CTL, no ownership interest will be earned by Veritas until the entire $1.5 million is received. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company's creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.
Edgenation
8 years ago
NEWS!!! Health Canada Final Review Notification Received For
ACMPR Application
February 21, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that, pursuant to the news release announced November 21, 2016, Sechelt Organic Marijuana Inc. (“Sechelt”), has been notified by Health Canada that it has successfully progressed into the Final Review stage of the ‘Access to Cannabis for Medical Purposes Regulations’ (ACMPR) application process. Veritas has been granted the exclusive option to acquire 100% ownership of Sechelt, subject to certain terms and conditions including; obtaining an ACMPR/MMPR license and the issuance of a permit by Health Canada for the building of a cannabis growing facility.
Sechelt currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada and, since July 4th, 2014, and has had an application pending with Health Canada for a new ACMPR license. Sechelt personnel includes an experienced grow master who is currently a ‘designated grower’ under current ACMPR licensing guidelines Health Canada will now assess Sechelt’s physical security plans to validate the information in its application.
“Sechelt sits with a minority of applicants who have successfully moved through the security clearance stage and into the final review stage,” stated Veritas CEO, Dr. Lui Franciosi. “We are excited by the prospect of Sechelt receiving its ACMPR license in due course, which is a significant development for it, Veritas and Cannevert.”
Veritas Pharma and Cannevert Therapeutics have been actively preparing for their first clinical trials of select cannabis strains targeting pain sometime this year. This scientific work forms the basis for Veritas’ future branding and traction in Canadian market, especially if Health Canada issues Sechelt a grower’s license. The Company will be in a better position to produce special varieties of cannabis that have the ideal therapeutic characteristics. Upon Cannevert Therapeutics completing the clinical evidence and Sechelt obtaining a production license, Veritas will be in a strong position to enter the United States with Marapharm Ventures Inc. as its key partner. Marapharm has significant ownership of Veritas.
Veritas would also like to announce that 400,000 stock options have been issued; 200,000 each to two consultants. The options will be vested immediately and have an exercise price of $0.47. The options will expire, if unexercised, in one year from date of issue. Further to the January 12, 2017 announcement of the issuance of warrants expiring on June 7, 2018, the Company has paid a 10% or $50,000 in finders’ fees to unrelated third parties.
About Sechelt Organic Medicine Inc.
Sechelt was formed to become a producer of medical marijuana under the ACMPR license. The products designed by Cannevert Therapeutics require the ability to grow specific strains of medical marijuana under ideal conditions. Sechelt provides Cannevert Therapeutics this ability.
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging discovery and IP development company, committed to advancing the science behind medical cannabis. The company’s current R&D efforts are being conducted through its strategic partner, Cannevert Therapeutics Ltd. (“CTL”). The ultimate objectives of our R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical science professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. To date, Veritas has advanced $750,000 to CTL and holds contingent ownership of, but not the voting rights over, 40.5% of the issued and outstanding common shares of CTL. Veritas will not acquire full ownership rights, including voting rights, over any CTL common shares until the entire $1.5 million has been paid. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas’ and CTL’s unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company, which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company's creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.
Edgenation
8 years ago
NEWS!!! Veritas-Cannavert Commences Preparation Of First Clinical Trials Of Cannabis Targeting Pain
February 7, 2017 Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that Dr. Ricardo Rivera Acevedo, a scientist within its research arm, Cannevert Therapeutics Ltd., has been invited to attend the Masterclass on Medicinal Cannabis in Leiden, The Netherlands from March 5-10, 2017.
Bedrocan, a multinational company that has been growing and supplying pharmaceutical grade medicinal cannabis since the early 1980s, hosts this 5-day seminar yearly. The selection process involves selecting from an international pool of applicants with diverse backgrounds and research interests from the industry. Bedocran’s Head of Research and Education, Dr. Arno Hazekamp, has brought together several world experts to review the historical significance, regulatory status, chemical composition, clinical research designs, quality control/assurance matters, and latest cultivation techniques related to medicinal cannabis.
Veritas CEO, Dr. Lui Franciosi stated that “We are very pleased to have one of the Cannevert scientists attend this event. It demonstrates Bedrocan’s interest in our scientific approach of using functional techniques to assess the potential of whole plant extracts for specific disease conditions. This event will maximize the exchange of best practices between professionals, including policy makers, who are actively involved in the medicinal cannabis industry.”
Edgenation
8 years ago
NEWS!!!
Veritas Pharma Places Final Payment In Trust For
The Acquisition Of Cannevert Therapeutics
January 25, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, has announced that it has placed its final payment of $250,000 to Cannevert Therapeutics Ltd. (CTL) (scheduled for May 1st, 2017) into a trust account. The completion of this payment will bring Veritas’ investment in CTL up to $1,500,000 granting an 80% ownership of CTL, with an option to purchase the additional 20%.
Completion of this transaction will enable CTL to focus on applying for further non-dilutive funding through various research grant applications. CTL has previously shown success in receiving grants. On October 20th, 2016, Veritas Pharma announced awarding of MITACS grant to CTL.
Veritas CEO, Dr. Franciosi, commented “We are excited to proceed rapidly and to solidify our agreement with Cannevert. As I have mentioned previously, the Cannevert scientists are a very capable team with a proven track record of creating substantial shareholder value. It is good to see that both Cannevert and Veritas are now well funded to further accelerate the scientific screening and identification of new products for the clinic.”
When asked about other upcoming milestones for the company, Dr. Franciosi commented, “We will be reviewing Cannevert’s current research progress as well as focusing on our Access to Cannabis for Medical Purposes Regulations (ACMPR) application, which are eagerly awaiting Health Canada’s decision. This was filed on July 4th 2014. Since then, we delivered on all their information requests and have been in good standing. We recently inquired about our status and we should be hearing back from them shortly.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging discovery and IP development company, committed to advancing the science behind medical cannabis. The company’s current R&D efforts are being conducted through its strategic partner, Cannevert Therapeutics Ltd. (“CTL”). The ultimate objectives of our R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical science professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. To date, Veritas has advanced $750,000 to CTL and holds contingent ownership of, but not the voting rights over, 40.5% of the issued and outstanding common shares of CTL. Veritas will not acquire full ownership rights, including voting rights, over any CTL common shares until the entire $1.5 million has been paid. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas’ and CTL’s unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company, which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Edgenation
8 years ago
NEWS!!!!!
Veritas Pharma Advances Fifth of Six Equal Payments to Cannevert Therapeutics Ltd.
Accesswire AccesswireJanuary 23, 2017
VANCOUVER, BC / ACCESSWIRE / January 23, 2017 / Veritas Pharma Inc. (CNSX:VRT) (OTC PINK: VRTHF) (2VP.F), an emerging discovery and IP development company, is pleased to announce that it has completed its second to last payment of $250,000 to Cannevert Therapeutics Ltd. (CTL). This latest installment brings Veritas' total investment in CTL to $1,250,000. An additional $250,000 needs to be paid by May 1st, 2017. The final payment will grant Veritas Pharma an 80% ownership interest in CTL, with an option to purchase the remaining 20%.
Cannevert has effectively been acting as the research arm of Veritas, as it currently has an exclusive license agreement to market all proprietary products developed by them. Additionally, all monetary advances made thus far have been used to expand CTL's R&D efforts. With the latest payment, CTL will provide Veritas with a report on its current research program. We anticipate to have it within the next 10 days, at which point the principal results will be announced.
Dr. Lui Franciosi, Veritas' CEO, stated "Cannevert team is composed of a veteran scientific team whom have previously developed successful pharmaceutical drugs and have created over a billion dollars in shareholder value along the way. I believe that our latest payment to Cannevert has solidified our commitment to each other and secures our continued collaboration. I would also like to extend my thanks to those who participated in the last financing, in particular Marapharm Ventures Inc., as it has enabled Veritas to bring this this transaction to the cusp of completion."
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect CTL's IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. All payments made by Veritas to date have been used to expand CTL's R&D efforts and this funding has partially been matched by research grants.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
"Dr. Lui Franciosi"
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
SOURCE: Veritas Pharma Inc.
Edgenation
8 years ago
NEWS!!!!!!
Veritas Newsletter: Thank You for Subscribing
View this email in your browser
News Release:
Veritas (CSE: “VRT”) Appoints Marapharm (CSE: “MDM”) Director Mr. Yari Nieken
January 18, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, has announced appointment of Mr. Yari Nieken as a director of the company. Mr. Nieken replaces Dr. Dom Spina who sadly passed away in December of 2016.
Mr. Nieken has a wide range of public company and capital market experience. He is Founder and President of Foremost Capital Inc. an Exempt Market Dealer. He is currently a director of Marapharm Ventures Inc. and has served on the boards of several public and private issuers including PUF Ventures (President & CEO), Lexagene Holdings Inc. (Director), Duport Capital Ltd (Director) and has raised substantial capital in his career. He holds an MBA from the Sydney Graduate School of Management and a BA from the University of British Columbia. He was formerly an investment advisor at Union Securities Corp. and continues to be a registrant in good standing in the provinces of British Columbia, Alberta, and Ontario.
Veritas’ CEO, Dr. Franciosi, commented, “I would like to welcome Mr. Nieken to the Veritas team and I am looking forward to working with him. Mr. Nieken brings a great wealth of experience to the company, specifically in areas of capital markets, growth strategies, and marketing. With the scientific work progressing rapidly and having now secured the necessary financing, Mr. Nieken’s experience will be very valuable as Veritas prepares to embark on its next steps of its journey.”
Mr. Nieken commented, “I am extremely excited to be joining the Board of Directors at Veritas Pharma. I believe that Veritas Pharma is uniquely positioned for growth within a very exciting segment of the pharmaceutical industry, and I am committed to contributing to this growth to the best of my abilities.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging discovery and IP development company, committed to advancing the science behind medical cannabis. The company’s current R&D efforts are being conducted through its strategic partner, Cannevert Therapeutics Ltd. (“CTL”). The ultimate objectives of our R&D efforts are to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for real science to support medical marijuana claims.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical science professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. To date, Veritas has advanced $750,000 to CTL and holds contingent ownership of, but not the voting rights over, 40.5% of the issued and outstanding common shares of CTL. Veritas will not acquire full ownership rights, including voting rights, over any CTL common shares until the entire $1.5 million has been paid. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas’ and CTL’s unique value proposition employs a whole plant methodology, using a low cost research and development model to help drive shareholder value and speed-to-market. The company’s commercial mission is to patent protect its IP (cultivars/ strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
Veritas Pharma Inc. is a publicly traded company, which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com
The CSE has not reviewed, nor approved or disapproved the content of this press release.
DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company's creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.
Veritas Investor Summary
More on Veritas
Recent News Releases:
Veritas Pharma Enters into Agreement to Secure ACMPR License and Cannabis Growing Facility
Veritas Announces an Expansion to the Private Placement and Engages European Healthcare Capital
Veritas Announces Cannimed Ltd. As The New Supplier Of Cannabis Strains For Animal Studies
Veritas Pharma Inc. Exclusive Partner Qualifies For Non-Dilutive Grant – Update
Veritas Corporate Video
Veritas in Media
You are receiving this email because you opted into our newsletter on veritaspharma.com
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
DISCLAIMER: Forward-Looking Information: This news release contains certain forward-looking information. All information, other than information regarding historic fact that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future is forward-looking information. The forward-looking information contained in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. With respect to the forward-looking information contained in this news release, the Company has made assumptions regarding, among other things, the results of the research and development activities, and the continued ability of the Company to raise additional financing. The forward-looking information contained in this news release is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from current expectations, including the any future changes to laws pertaining to the use of cannabis derived pharmaceuticals, prices and demand for cannabis derived pharmaceuticals, future currency and interest rates. Additionally, if the Company is unable to obtain additional financing, the Company may be required to curtail activities and/or liquidate its assets or the Company’s creditors may seek to seize its assets. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable law, the Company disclaims any obligation to update or modify such forward-looking information, either because of new information, future events or for any other reason. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The CSE has not reviewed, nor approved or disapproved the contents of this press release.
Our mailing address is:
101 – 2386 East Mall
University of British Columbia
Vancouver, BC V6T 1Z3
Facebook
Website
LinkedIn
Copyright © 2016 Veritas Pharma Inc, All rights reserved.
Email Marketing Powered by MailChimp
Edgenation
8 years ago
NEWS!!!
Veritas Receives Listing On The XETRA® (Frankfurt, Germany) Trading Venue
December 8, 2016, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that as of December 7th, 2016, its common shares are accepted for continuous trading on the electronic trading platform XETRA® on the Frankfurt Exchange under the symbol 2VP. Veritas Pharma’s management expects that a listing through Xetra® will provide higher liquidity and more efficient market pricing for the company’s common shares.
Veritas CEO, Dr. Franciosi, stated “this is a very exciting development and we are proud to be accepted for trading on the Xetra® platform. Xetra® is a more senior European trading venue and I believe that this will be an important step in introducing our company to a wider range of qualified retail and institutional investors.”
About Xetra®
Xetra® is an all-electronic trading system based in Frandkfurt, Germany. It was launched in 1997 and is operated by the Deutsche Börse. Eventhough Xetra® was originally designed for the Frankfurt Stock Exchange, it has since expanded to various European exchanges. Xetra® trading venue supports more than 90 percent of all shares trading within Germany.1 Xetra®, through its platform, offers increased visibility for order depths and offers trading of stocks, funds, bonds, warrants, and commodities. “In addition to the Frankfurt trading platform, international partner exchanges also use its trading technology, including the Bulgarian Stock Exchange, the Irish Stock Exchange and the Malta Stock Exchange and Wiener Börse AG. The world’s largest exchange network connects 4,000 traders from 16 European countries plus Hong Kong and the United Arab Emirates.”1
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
WallWeeD
6 years ago
